natgillin/translations-raw huggingface dataset:
All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with Ibandronic Acid Teva. 
Vsem bolnikom je treba naročiti, naj med zdravljenjem z zdravilom Ibandronska kislina Teva skrbijo za dobro ustno higieno in redno opravljajo preglede pri zobozdravniku, v primeru simptomov v ustni votlini, kot so majavost zob, bolečina, oteklina, slabo celjenje ali izcedek iz ran, pa naj takoj obvestijo zdravnika.
Oesophagitis, Gastritis, Gastro oesophageal reflux disease, Dyspepsia, Diarrhoea, Abdominal pain, Nausea 
Bolezni prebavil* ezofagitis, gastritis, gastroezofagealna refluksna bolezen, dispepsija, driska, abdominalna bolečina, navzea ezofagitis,
The absorption of ibandronic acid in the upper gastrointestinal tract is rapid after oral administration and plasma concentrations increase in a dose-proportional manner up to 50 mg oral intake, with greater than dose-proportional increases seen above this dose. 
Po peroralnem jemanju je absorpcija ibandronske kisline v zgornjem delu prebavil hitra, koncentracije v plazmi naraščajo v odvisnosti od odmerka do peroralnega vnosa 50 mg, pri večjih vnosih pa so opazili večje poraste koncentracij v plazmi od sorazmernih z odmerkom.
4.4 Special warnings and precautions for use 
4.4 Posebna opozorila in previdnostni ukrepi Hipokalciemija
Therefore dosage adjustment is not necessary in patients with hepatic impairment. 
Zato bolnikom z okvaro jeter ni treba prilagoditi odmerkov.
Clinical efficacy 
UČINKOVITO UPORABO ZDRAVILA
The management plan of the patients who develop ONJ should be set up in close collaboration between the treating physician and a dentist or oral surgeon with expertise in ONJ. 
Za bolnike, pri katerih se razvije osteonekroza čeljustnic, morata načrt zdravljenja v tesnem sodelovanju pripraviti lečeči zdravnik in zobozdravnik oziroma oralni kirurg, ki ima izkušnje z zdravljenjem osteonekroze čeljustnic.
Subjects with severe renal impairment (CLcr ≤ 30 mL/min) receiving oral administration of 10 mg ibandronic acid daily for 21 days, had 2-3 fold higher plasma concentrations than subjects with normal renal function (CLcr ≥80 mL/min). 
Bolniki s hudo ledvično okvaro (CLcr ≤ 30 ml/min), ki so peroralno prejemali 10 mg ibandronske kisline dnevno 21 dni, so imeli 2-3- krat večje plazemske koncentracije kot bolniki z normalnim delovanjem ledvic (CLcr ≥ 80 ml/min).
- If you are allergic to ibandronic acid or any of the other ingredients of this medicine listed in section 6. 
- če ste alergični na ibandronsko kislino ali katero koli drugo sestavino tega zdravila (navedeno v poglavju 6).
Fri. 
• izpuščaj.
At two years the median relative change was -68 % and -62 %, in the 150 mg monthly and 2.5 mg daily arms respectively. 
Po dveh letih je bila mediana relativne spremembe -68 % za mesečno odmerjanje 150 mg in -62 % za dnevno odmerjanje 2,5 mg.
Oesophagitis including oesophageal ulcerations or strictures and dysphagia, Vomiting, Flatulence 
vključno z ezofagealnimi ulceracijami ali zožitvami ter disfagijo, bruhanje, flatulenca duodenitis
PHARMACEUTICAL FORM AND CONTENTS Film-coated tablet 
FARMACEVTSKA OBLIKA filmsko obložena tableta
Do not take Ibandronic Acid Teva if you are pregnant or breast feeding. 
Ne jemljite zdravila Ibandronska kislina Teva, če ste noseči ali dojite.
In addition, ibandronic acid does not inhibit the major human hepatic P450 isoenzymes and does not induce the hepatic cytochrome P450 system in rats. 
Dodatno ibandronska kislina pri ljudeh ne zavira glavnih jetrnih izoencimov P450, pri podganah pa ne spodbuja jetrnega citokroma P450.
This could be a sign of an ulcer of the first section of the bowel 
Te so lahko znak, da razjeda v začetnem delu črevesa (dvanajstniku)
SMPR (per patient year) 
vrednost p stopnja hitrosti obolevnosti okostja (na bolnikova leta)
Osteonecrosis of the external auditory canal has been reported with bisphosphonates, mainly in association with long-term therapy. 
Pri zdravljenju z difosfonati so poročali o osteonekrozi zunanjega sluhovoda, predvsem v povezavi z dolgotrajnim zdravljenjem.
Studies in rats have shown some reproductive toxicity (see section 5.3). 
Študije na podganah so pokazale, da zdravilo nekoliko vpliva na sposobnost razmnoževanja (glejte poglavje 5.3).
Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction)† 
osteonekroza zunanjega sluhovoda (neželeni učinek skupine difosfonatov)
After intravenous administration of 0.5 mg, total, renal, and non-renal clearances decreased by 67 %, 77 % and 50 %, respectively, in subjects with severe renal failure but there was no reduction in tolerability associated with the increase in exposure. 
Po intravenskem dajanju odmerka 0,5 mg se je pri bolnikih s hudo okvaro ledvic skupni očistek zmanjšal za 67 %, ledvični očistek za 77 %, neledvični očistek pa za 50 %.
The liver has no significant role in the clearance of ibandronic acid since it is not metabolized but is cleared by renal excretion and by uptake into bone. 
Jetra niso pomembna za očistek ibandronske kisline, ker se ta ne presnavlja, ampak izloča skozi ledvice in prevzema v kostno tkivo.
Due to limited clinical experience, Ibandronic Acid Teva is not recommended for patients with a creatinine clearance below 30 ml/min (see section 5.2). 
Zaradi malo kliničnih izkušenj zdravila Ibandronska kislina Teva ne priporočamo bolnikom, ki imajo kreatininski očistek manjši kot 30 ml/min (glejte poglavje 5.2).
Talk to your doctor before taking Ibandronic Acid Teva: - If you have any disturbances of mineral metabolism (such as vitamin D deficiency). 
- Če imate kakršne koli motnje presnove mineralov (kot je pomanjkanje vitamina D).
• new pain, weakness or discomfort in your thigh, hip or groin. 
• nova bolečina, šibkost ali nelagodje v stegnu, kolku ali dimljah.
Studies in rats have shown reproductive toxicity (see section 5.3). 
Študije na podganah so pokazale vpliv na sposobnost razmnoževanja (glejte poglavje 5.3).
Ibandronic acid 50 mg n=287 
ibandronska kislina (50 mg) n = 287
No dose adjustment is necessary for patients with mild or moderate renal impairment (CLcr equal or greater than 30 ml/min), as shown in study BM 16549 where the majority of patients had mild to moderate renal impairment. 
prilagajanje odmerkov ni potrebno, kar se je pokazalo v študiji BM 16549, kjer je večina bolnikov imela blago do zmerno okvaro ledvic.
Adverse effects of ibandronic acid in reproductive toxicity studies in the rat were those expected for this class of medicinal products (bisphosphonates). 
Neželeni učinki ibandronske kisline v študijah vpliva na sposobnost za razmnoževanje pri podganah so bili značilni za to skupino zdravil (difosfonati).
Uncommon (may affect less than 1 in 100 people): 
Občasni (pojavijo se lahko pri manj kot 1 od 100 bolnikov):
Anaphylactic reaction/shock* 
anafilaktična reakcija/šok†
NAME OF THE MARKETING AUTHORISATION HOLDER Teva B.V. 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Teva B.V.
You may have early signs of severe jaw problems (necrosis 
Lahko imate zgodnje znake resnih težav s čeljustmi
MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 
IZDELOVALCI, ODGOVORNI ZA SPROŠČANJE SERIJ
Patients with known hypersensitivity to other bisphosphonates Caution is to be taken in patients with known hypersensitivity to other bisphosphonates. 
Previdnost je potrebna pri bolnikih z znano preobčutljivostjo za druge difosfonate.
Table 2: Mean relative change from baseline of lumbar spine, total hip, femoral neck and trochanter BMD after one year (primary analysis) and two years of treatment (Per-Protocol Population) in study BM 16549. 
Preglednica 2: povprečna relativna sprememba od izhodiščne vrednosti MKG ledvene hrbtenice, kolka, stegneničnega vratu in trohantra po enem letu (primarna analiza) in dveh letih zdravljenja
How to store Ibandronic Acid Teva Content of the pack and other information 
Shranjevanje zdravila Ibandronska kislina Teva Vsebina pakiranja in dodatne informacije
Biotransformation There is no evidence that ibandronic acid is metabolised in animals or humans. 
Biotransformacija Ni dokazov, da bi se ibandronska kislina pri ljudeh ali živalih presnavljala.
Osteonecrosis of the external auditory canal 
Osteonekroza zunanjega sluhovoda
Ibandronic Acid Teva 150 mg: Medicinal product subject to medical prescription. 
Ibandronska kislina Teva 150 mg: Predpisovanje in izdaja zdravila je le na recept.
There are no data on the effects of ibandronic acid in humans. 
O vplivu ibandronske kisline pri ljudeh ni podatkov.
Posology The recommended dose is one 50 mg film-coated tablet daily. 
Odmerjanje Priporočeni odmerek je ena 50 mg filmsko obložena tableta dnevno.
No specific information is available on the treatment of overdose with Ibandronic Acid Teva. 
Na voljo ni nobenih posebnih podatkov o zdravljenju prevelikega odmerka zdravila Ibandronska kislina Teva.
Children and adolescents Ibandronic Acid Teva should not be used in children and adolescents below the age of 18 years. 
Zdravilo Ibandronska kislina Teva se ne sme uporabljati pri otrocih in mladostnikih, starih manj kot 18 let.
• tablet core: cellulose microcrystalline, povidone K-30, crospovidone (type A), silica colloidal anhydrous, stearic acid; 
Jedro tablete: mikrokristalna celuloza povidon K-30 krospovidon (tipa A) koloidni brezvodni silicijev dioksid stearinska kislina
However, since this increase is within the normal variability of the bioavailability of ibandronic acid, no dose adjustment is considered necessary when Ibandronic Acid Teva is administered with H2-antagonists or other active substances which increase gastric pH. 
Ker je to povečanje v mejah normalne variabilnosti biološke uporabnosti ibandronske kisline, pri sočasnem jemanju zdravila Ibandronska kislina Teva s H2-antagonisti ali drugimi zdravili,
However, oral overdosage may result in upper gastrointestinal events, such as upset stomach, heartburn, oesophagitis, gastritis or ulcer. 
Vendar lahko preveliko peroralno odmerjanje povzroči neželene dogodke v zgornjih prebavilih, kot so razdražen želodec, zgaga, ezofagitis, gastritis ali razjeda.
They are designed to help your Ibandronic Acid Teva tablet reach your stomach quickly, so it's less likely to cause irritation. 
Zasnovana so tako, da bo tableta Ibandronska kislina Teva hitro dosegla vaš želodec.
Ibandronic Acid Teva is only for use in postmenopausal women and must not be taken by women of childbearing potential. 
Zdravilo Ibandronska kislina Teva lahko uporabljajo samo ženske v postmenopavzi, ženske v rodni dobi pa ga ne smejo uporabljati.
However, based on a knowledge of this class of compounds, oral overdose may result in upper gastrointestinal adverse reactions (such as upset stomach, dyspepsia, oesophagitis, gastritis, or ulcer) or hypocalcaemia. 
Glede na podatke o tej skupini zdravil lahko preveliko peroralno odmerjanje povzroči neželene učinke v zgornjem delu prebavil (kot so razdražen želodec, dispepsija, ezofagitis, gastritis ali razjeda) ali hipokalciemijo.
Ibandronic acid leads to progressive net gains in bone mass and a decreased incidence of fractures through the reduction of elevated bone turnover towards premenopausal levels in postmenopausal women. 
Ibandronska kislina povzroči progresivno čisto povečanje kostne mase in zmanjša incidenco zlomov, tako da pri ženskah po menopavzi zmanjša povečano razmerje med razgradnjo in tvorbo kosti in ga približa razmerju pred menopavzo.
Patients with disturbances of bone and mineral metabolism Hypocalcaemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Ibandronic Acid Teva therapy. 
Pred začetkom zdravljenja z zdravilom Ibandronska kislina Teva je treba učinkovito zdraviti hipokalciemijo ter druge motnje kosti in presnove mineralov.
Among these patients, the incidence of upper gastrointestinal events in the patients treated with ibandronic acid 150 mg once monthly was similar to that in patients treated with ibandronic acid 2.5 mg daily. 
Pri teh bolnikih je bila incidenca neželenih učinkov v zgornjem delu prebavil podobna pri tistih, ki so se zdravili z ibandronsko kislino 150 mg enkrat na mesec ali ibandronsko kislino 2,5 mg vsak dan.
Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment. 
Pri bolnikih, pri katerih obstaja sum na atipičen zlom stegnenice, je treba razmisliti o prekinitvi zdravljenja z difosfonati do pregleda, na katerem bo ovrednoteno razmerje med koristmi in tveganji za posameznega bolnika.
• if you are allergic to ibandronic acid or any of the other ingredients of this medicine that are listed in section 6 
- če ste alergični na ibandronsko kislino ali katero koli drugo sestavino tega zdravila (navedeno v poglavju 6);
While no increased risk was observed in controlled clinical trials there have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications. 
Čeprav v nadzorovanih kliničnih raziskavah niso opazili povečanega tveganja, pa so v obdobju po prihodu zdravila na trg poročali o razjedah želodca in dvanajstnika v povezavi s peroralnimi difosfonati.
H2 blockers or proton pump inhibitors 
Antagonisti histaminskih receptorjev H2 in zaviralci protonske črpalke
Hypersensitivity to ibandronic acid or to any of the excipients listed in section 6.1. 
- Preobčutljivost na ibandronsko kislino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Products containing calcium and other multivalent cations (such as aluminium, magnesium, iron), including milk and food, are likely to interfere with absorption of Ibandronic Acid Teva tablets. 
Pripravki, ki vsebujejo kalcij in druge večvalentne katione (kot so aluminij, magnezij, železo), vključno z mlekom in hrano, lahko vplivajo na absorpcijo zdravila Ibandronska kislina Teva tablete.
How to take Ibandronic Acid Teva). 
Kako jemati zdravilo Ibandronska kislina Teva).
The liver has no significant role in the clearance of ibandronic acid which is not metabolised but is cleared by renal excretion and by uptake into bone. 
Jetra niso pomembna za očistek ibandronske kisline, ker se ta ne presnavlja, ampak izloča skozi ledvice in z vstopanjem v kostno tkivo.
This was a composite endpoint which had the following skeletal related events (SREs) as sub-components: 
Ta cilj raziskave je sestavljalo več z okostjem povezanih dogodkov:
- Patients should not lie down for 1 hour after taking Ibandronic Acid Teva. 
- Bolnik se ne sme uleči še eno uro po tem, ko je vzel zdravilo Ibandronska kislinaTeva.
Blood parathyroid hormone increased 
Preiskave zvišan paratiroidni hormon v krvi
Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when Ibandronic Acid Teva is given to patients with active upper gastrointestinal problems (e.g. known Barrett's oesophagus, dysphagia, other oesophageal diseases, gastritis, duodenitis or ulcers). 
Zaradi draženja in možnosti poslabšanja že obstoječe bolezni je potrebna pri bolnikih z obstoječimi težavami v zgornjem delu prebavil (npr. Barrettov požiralnik, disfagija ali druge bolezni požiralnika, gastritis, duodenitis ali razjede) previdnost pri uporabi zdravila Ibandronska kislina Teva.
Skin and subcutaneous tissue disorders 
Bolezni kože in podkožja pruritus
Ibandronic Acid Teva comes in blisters (PVC/Aclar/PVC - Aluminium) in cartons of 1 or 3 tablets. 
Zdravilo Ibandronska kislina Teva je na voljo v pretisnih omotih (PVC/Aclar/PVC in aluminij) v kartonskih škatlah, ki vsebujejo 1 ali 3 tablete.
Tabulated list of adverse reactions 
Tabelarični prikaz neželenih učinkov
In reproductive studies in rats by the oral route, ibandronic acid decreased fertility. 
V študijah vplivov na sposobnost razmnoževanja pri podganah, v katerih so ibandronsko kislino dajali peroralno, je ta zmanjšala plodnost.
Do not pass it on to others. 
ne vzemite drugih zdravil.
Ibandronic Acid Teva comes in blisters (PVC/Aclar/PVC - Aluminium) in cartons of 28 or 84 tablets. 
Zdravilo Ibandronska kislina Teva je na voljo v pretisnih omotih (PVC/Aclar/PVC in aluminij) v kartonskih škatlah, ki vsebujejo 28 ali 84 tablet.
If you forget to take Ibandronic Acid Teva 
Če ste pozabili vzeti zdravilo Ibandronska kislina Teva
• dry mouth, strange taste in your mouth or difficulty swallowing 
- suha usta, čuden okus v ustih, težave pri požiranju, - anemija (slabokrvnost),
However, early plasma levels fall quickly, reaching 10% of peak values within 3 and 8 hours after intravenous or oral administration respectively. 
Vendar se zgodnje koncentracije v plazmi hitro znižajo; 3 ure po intravenskem dajanju in 8 ur po peroralnem dajanju dosežejo 10 % najvišje vrednosti.
Ibandronic acid 150 mg once monthly was shown to be at least as effective as ibandronic acid 2.5 mg daily at increasing BMD in a two year, double-blind, multicentre study (BM 16549) of postmenopausal women with osteoporosis (lumbar spine BMD T score below -2.5 SD at baseline). 
Ibandronska kislina v odmerku 150 mg enkrat mesečno se je v dveletni dvojno slepi, multicentrični študiji (BM 16549) pri ženskah z osteoporozo v postmenopavzi (izhodiščna T-vrednost MKG ledvene hrbtenice pod -2,5 SD) glede povišanja MKG izkazala za najmanj enako učinkovito kakor ibandronska kislina v odmerku 2,5 mg enkrat dnevno.
Ibandronic acid 150 mg once monthly 
ibandronska kislina 150 mg enkrat mesečno
Relative Risk Reduction New morphometric vertebral fractures 
zmanjšanje relativnega tveganja novi zlomi vretenc (določeno morfometrično)
At one year (primary analysis), 91.3 % (p=0.005) of patients receiving ibandronic acid 150 mg once monthly had a lumbar spine BMD increase above or equal to baseline (BMD responders), compared with 84.0 % of patients receiving ibandronic acid 2.5 mg daily. 
Po enem letu (primarna analiza) se je 91,3 % (p = 0,005) bolnikom, ki so prejemali 150 mg ibandronske kisline enkrat mesečno, MKG ledvene hrbtenice povišala ali ostala enaka izhodiščni vrednosti (bolniki, odzivni na povišanje MKG) v primerjavi s 84,0 % bolnikov, ki so prejemali 2,5 mg ibandronske kisline dnevno.
Since Nonsteroidal Anti-Inflammatory medicinal products and bisphosphonates are both associated with gastrointestinal irritation, caution should be taken during concomitant administration. 
Ker nesteroidna protivnetna zdravila in difosfonate povezujejo z gastrointestinalnim draženjem, je pri sočasnem peroralnem jemanju teh zdravil potrebna previdnost.
The start of treatment or of a new course of treatment should be delayed in patients with unhealed open soft tissue lesions in the mouth. 
Pri bolnikih z nezaceljenimi odprtimi lezijami mehkih tkiv v ustih je treba odložiti začetek zdravljenja ali začetek novega ciklusa zdravljenja.
If you stop taking Ibandronic Acid Teva 
Če ste prenehali jemati zdravilo Ibandronska kislina Teva
Bioavailability is reduced by about 90% when ibandronic acid is administered with a standard breakfast in comparison with bioavailability seen in fasted subjects. 
Pri sočasnem uživanju ibandronske kisline s standardnim zajtrkom se biološka uporabnost zmanjša za okoli 90 % v primerjavi z biološko uporabnostjo, ki so jo opazili pri teščih bolnikih.
Orally administered bisphosphonates may cause local irritation of the upper gastrointestinal mucosa. 
Peroralno aplicirani difosfonati lahko povzročijo lokalno draženje sluznice zgornjega dela prebavil.
- If you have any swallowing or digestive problems. 
- Če imate težave s požiranjem ali prebavne motnje.
Do not take Ibandronic Acid Teva if you are pregnant, planning to get pregnant or if you are breast-feeding. 
Nosečnost in dojenje Zdravila Ibandronska kislina Teva ne smete jemati, če ste noseči, poskušate zanostit ali če dojite.
The primary endpoint of the trials was the skeletal morbidity period rate (SMPR). 
Primarni cilj raziskave je bil stopnja hitrosti obolevnosti okostja.
Therefore, it is recommended that the tablets should be taken after an overnight fast (minimum 6 hours) and fasting should continue for at least 30 minutes after the dose has been taken (see section 4.2). 
Zato priporočamo, da bolnik zaužije tablete po postu prek noči (post naj traja najmanj 6 ur), po zaužitem odmerku pa naj počaka še najmanj 30 minut pred pitjem ali hranjenjem (glejte poglavje 4.2).
Table 1 Adverse Drug Reactions Reported for Oral Administration of Ibandronic Acid 
Preglednica 1: neželeni učinki, o katerih so poroča pri peroralni uporabi ibandronske kisline
Therefore, it is recommended that the tablets should be taken after an overnight fast (at least 6 hours) and fasting should continue for at least 30 minutes after the dose has been taken (see section 4.2). 
Zato se priporoča, da bolnik vzame tablete po nočnem postu (post naj traja najmanj 6 ur), po vzetem odmerku pa mora miniti še vsaj 30 minut, preden bolnik zaužije pijačo ali hrano (glejte poglavje 4.2).
A dental examination with preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with Ibandronic Acid Teva in patients with concomitant risk factors. 
Pri bolnikih s spremljajočimi dejavniki tveganja je pred začetkom zdravljenja z zdravilom Ibandronska kislina Teva priporočljivo opraviti zobozdravniški pregled z ustreznimi preventivnimi zobozdravstvenimi ukrepi in oceniti razmerje med koristmi in tveganji pri vsakem posameznem bolniku.
A statistically significant improvement in bone pain score was shown for ibandronic acid 50 mg compared to placebo. 
V primerjavi s placebom se je pri ibandronski kislini v 50 mg odmerkih pokazalo statistično pomembno izboljšanje rezultata pri bolečinah v kosteh.
- Patients should not chew , suck or crush the tablet because of a potential for oropharyngeal ulceration. 
- Bolnik tablete ne sme žvečiti, sesati ali drobiti, ker obstaja nevarnost za nastanek razjede v ustih in žrelu.
Each film-coated tablet contains 150 mg ibandronic acid (as sodium monohydrate). 
Ena filmsko obložena tableta vsebuje 150 mg ibandronske kisline (v obliki natrijevega monohidrata).
Early plasma levels fall quickly reaching 10 % of peak values within 3 and 8 hours after intravenous or oral administration respectively. 
Zgodnje koncentracije v plazmi se hitro znižajo, 3 ure po intravenskem dajanju in 8 ur po peroralnem dajanju dosežejo 10 % največje vrednosti.
Headache Dizziness 
Vnetje oči
In particular, tell your doctor or pharmacist if you are taking any of the following medicines: - supplements containing calcium, magnesium, iron or aluminium - acetylsalicylic acid and non-steroidal anti-inflammatory medicines called “NSAIDs”, such as ibuprofen or naproxen. 
Še posebej obvestite svojega zdravnika ali farmacevta, če jemljete katere koli izmed naslednjih zdravil: - dodatke, ki vsebujejo kalcij, magnezij, železo ali aluminij.
No dose adjustment is required (see section 5.2). 
Prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
When a more stringent criterion is considered, which combines both lumbar spine and total hip BMD, 83.9 % (p<0.001) and 65.7 % of patients receiving ibandronic acid 150 mg once monthly or ibandronic acid 2.5 mg daily, respectively, were responders at one year. 
Če upoštevamo strožji kriterij, ki združuje MKG ledvene hrbtenice in kolka, je bilo po enem letu odzivnih 83,9 % (p < 0,001) bolnikov, ki so prejemali 150 mg ibandronske kisline enkrat mesečno, in 65,7 % bolnikov, ki so prejemali 2,5 mg ibandronske kisline dnevno.
PVC/Aclar/PVC - Aluminium blisters in cardboard boxes of 28 or 84 tablets. 
Pretisni omoti iz PVC/Aclar/PVC in aluminija v kartonskih škatlah, ki vsebujejo 28 ali 84 tablet.
Children and adolescents Do not give Ibandronic Acid Teva to children or adolescents below 18 years. 
Zdravila Ibandronska kislina Teva ne dajajte otrokom in mladostnikom, mlajšim od 18 let.
This is because NSAIDs and Ibandronic Acid Teva can both irritate your stomach and gut 
NSAID in zdravilo Ibandronska kislina Teva, ki lahko dražijo želodec in črevo.
Ibandronic acid 2.5 mg daily 
Ibandronska kislina v odmerku 2,5 mg dnevno